1
0
0
(1 - 25 von 31
)
Ellinghaus, Peter [WorldCat Identities]
worldcat.org
Ellinghaus, Peter ; Peter Ellinghaus( Book ) 3 editions published in ; Carla Jennewein( ) 1 edition published in ; Thomas Mondritzki( ) 1 edition published in ; › viaf
18 F-FAZA PET Imaging Response Tracks the Reoxygenation ...AACR Journals
aacrjournals.org
von E Chang · · Zitiert von: 28 — Peter Ellinghaus;. Peter Ellinghaus. 2Bayer Pharma AG, Global Drug Discovery, Wuppertal, Germany. Search for other works by this author on:. › article-a...
Abstract - ASCO MeetingAmerican Society of Clinical Oncology
meetings.asco.org
... Jian-Ri Li, Xavier Garcia del Muro, Florence Joly, Zsuzsanna Papai, Peter Ellinghaus, Chengxing Lu, Keiko Nakajima, Tatiane Ishida, Hiroyuki Nishiyama, ... › abstrac...
Cardiovascular Diabetology - ProQuestProQuest
search.proquest.com
von W Dinh · · Zitiert von: 163 — kliniken.de; Thomas Krahn - ; Peter Ellinghaus - ;. › openview › 1.pdf
Chronic inhibition of phosphodiesterase 5 does not prevent ...Oxford University Press
academic.oup.com
von S Schäfer · · Zitiert von: 87 — Peter Ellinghaus,. Peter Ellinghaus. 2. Target Discovery. ,. Bayer Schering Pharma. ,. Wuppertal. ,. Germany. Search for other works by this author on:. › articl...
Program Guide – ASCO Meeting Program Guidemeetings.asco.org › abstracts-presentations
meetings.asco.org
... Jae-Lyun Lee, Andrea Necchi, Nicolas Penel, Vittorina Zagonel, Mitchell Robert Sierecki, Ana-Maria Piciu, Peter Ellinghaus, Randy F. Sweis ...
Plasma galectin 3 is increased in terminal heart failure ...
www.sciencegate.app
Peter Ellinghaus ◽. Michael Seewald ◽. Hamdin Cakar ◽. Birte Bohms ◽ ... Keyword(s):. Heart Failure ◽. Myocardial Fibrosis ◽. › doc...
[PDF] Rogaratinib: A potent and selective pan-FGFR inhibitor with broad ...www.scienceopen.com › document_file › PubMedCentral
www.scienceopen.com
Peter Ellinghaus. 2. , Dominik Mumberg. 1. ,. Holger Hess-Stumpp. 1 and Karl Ziegelbauer Bayer AG, Berlin, Germany. 2Bayer AG, Wuppertal, Germany.
Regorafenib (BAY ): Antitumor and antimetastatic ...
www.scienceopen.com
... Tina Müller , Nicole Kahmann , Peter Ellinghaus , Robert Adams , André Rosenthal , Karl-Heinz Thierauch , Arne Scholz , Scott M Wilhelm , Dieter Zopf. › do...
Targeting the causes of cancer - BayerBayer
www.bayer.com
Peter Ellinghaus, senior scientist in On- cology Research at Bayer. For cancer researchers, this diversity is a curse and a blessing at the same time – on the ... › sites › files › research-31
What makes a good drug target?csmres.co.uk
csmres.co.uk
von I Gashaw · · Zitiert von: 293 — Peter Ellinghaus. 2. , Anette Sommer. 1 and Khusru Asadullah Global Drug Discovery – Target Discovery, Bayer HealthCare, ... › Gashaw_a24065
https://pub.h-brs.de/citationExport/index/download...pub.h-brs.de › download › output › bibtex › docId
pub.h-brs.de
... author = {Diana C. Lenhard and Hubertus Pietsch and Martin A. Sieber and Rainer Ernst and Philipp Lengsfeld and Peter Ellinghaus and Gregor Jost}, ...
role for coagulation factor Xa in experimental pulmonary arterial ...academic.oup.com › cardiovascres › article-abstract
academic.oup.com
Peter Ellinghaus,. Peter Ellinghaus. 2. Target Discovery, Bayer HealthCare. ,. Wuppertal. ,. Germany. Search for other works by this author on:.
sortiert nach Relevanz / Datum